JAK2 and diabetic kidney disease: The causal role of the pathway was supported by podocyte-specific overexpression of JAK2 and treatment of mice with an oral JAK inhibitor (Zhang et al. 2017), ultimately leading to a phase 2 clinical trial in diabetic kidney disease.